Literature DB >> 22551521

Identification of the ortho-benzoquinone intermediate of 5-O-caffeoylquinic acid in vitro and in vivo: comparison of bioactivation under normal and pathological situations.

Cen Xie1, Dafang Zhong, Xiaoyan Chen.   

Abstract

5-O-Caffeoylquinic acid (5-CQA) is one of the major bioactive ingredients in some Chinese herbal injections. Occasional anaphylaxis has been reported for these injections during their clinical use, possibly caused by reactive metabolites of 5-CQA. This study aimed at characterizing the bioactivation pathway(s) of 5-CQA and the metabolic enzyme(s) involved. After incubating 5-CQA with GSH and NADPH-supplemented human liver microsomes, two types of GSH conjugates were characterized: one was M1-1 from the 1,4-addition of GSH to ortho-benzoquinone intermediate; the other was M2-1 and M2-2 from the 1,4-addition of GSH directly to the α,β-unsaturated carbonyl group of the parent. The formation of M1-1 was cytochrome P450 (P450)-mediated, with 3A4 and 2E1 as the principal catalyzing enzymes, whereas the formation of M2-1 and M2-2 was independent of NADPH and could be accelerated by cytosolic glutathione transferase. In the presence of cumene hydroperoxide, M1-1 formation increased 6-fold, indicating that 5-CQA can also be bioactivated by P450 peroxidase under oxidizing conditions. Furthermore, M1-1 could be formed by myeloperoxidase in activated human leukocytes, implying that 5-CQA bioactivation is more likely to occur under inflammatory conditions. This finding was supported by experiments on lipopolysaccharide-induced inflammatory rats, where a greater amount of M1-1 was detected. In S-adenosyl methionine- and GSH-supplemented human S9 incubations, M1-1 formation decreased by 80% but increased after tolcapone-inhibited catechol-O-methyltransferase (COMT) activity. In summary, the high reactivities of the ortho-benzoquinone metabolite and α,β-unsaturated carbonyl group of 5-CQA to nucleophiles have been demonstrated. Different pathological situations and COMT activities in patients may alter the bioactivation extent of 5-CQA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551521     DOI: 10.1124/dmd.112.045641

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Liver protein targets of hepatotoxic 4-bromophenol metabolites.

Authors:  Yakov M Koen; Heather Hajovsky; Ke Liu; Todd D Williams; Nadezhda A Galeva; Jeffrey L Staudinger; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2012-08-03       Impact factor: 3.739

2.  Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.

Authors:  Cen Xie; Jialan Zhou; Zitao Guo; Xingxing Diao; Zhiwei Gao; Dafang Zhong; Haoyuan Jiang; Lijia Zhang; Xiaoyan Chen
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa.

Authors:  Lan Lu; Yuting Zhao; Guojuan Yi; Mingxing Li; Li Liao; Chen Yang; Chihin Cho; Bin Zhang; Jie Zhu; Kun Zou; Qiang Cheng
Journal:  Chin Med       Date:  2021-08-06       Impact factor: 5.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.